Last updated on April 24, 2014 at 17:35 EDT

GlySure Appoints Heidi Hausner as U.S. Director of Clinical Affairs

August 1, 2012

ABINGDON, England, August 1, 2012 /PRNewswire/ –

GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems,
today announced the appointment of Heidi Hausner, RN as its U.S. Director of Clinical
Affairs. In this newly established position, Hausner will lead U.S. clinical regulatory
trials for GlySure’s CGM technology and support the company’s clinical trials in Europe.

Hausner has more than 25 years of experience in both the manufacturing sector
directing all aspects of medical device clinical trials, as well as sales field training
and project management and in the clinical setting as a critical care operating room (OR)

Hausner most recently served as Senior Clinical Research Manager for Synthes, a market
leader in trauma, cranio/maxillofacial and spine industries (now part of Johnson &
Johnson), where she led the teams responsible for clinical investigations in both pre- and
post-market environments.

“Hausner’s strong background in clinical care and medical device trial management will
be an invaluable asset as we embark on our U.S. and European trials this fall,” said
GlySure CEO Chris Jones. “Her experience both at the patient bedside and behind the scenes
in product development and sales training will help drive the development of technology
that meets the clinical demand for CGM while improving the efficiency and reducing the
cost of care.”

Hausner holds a Master of Science degree in Quality Assurance and Regulatory Affairs
and a certificate in Clinical Trial Management from Temple University School of Pharmacy,
a Bachelor of Health Science in Management degree from Gwynedd Mercy College and a diploma
in Nursing from St. Luke’s Hospital School of Nursing.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors which can provide
continuous glucose readings throughout the length of a patient’s stay in the ICU. GlySure
was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20
employees. The company’s products are not approved for use in the U.S. or Europe.


        Company Contact: Chris Jones, CEO, GlySure, Tel: +44(0)1235-462-870,
        Media Contact: Bruce Dodworth, Sea Glass PR, Tel: +44(0)1780-769069,

SOURCE GlySure Limited

Source: PR Newswire